Aveanna’s Heartways Program Receives CHAP Disease Program Certification

Rhea-AI Summary

Aveanna Healthcare (NASDAQ: AVAH) announced that Aveanna Home Health and Hospice earned CHAP Disease Program Certification for Heart Failure on Feb 11, 2026. CHAP certification recognizes program structure, clinician education, quality metrics, and patient self-management tools under nationally recognized standards.

The certified Heartways program provides evidence-based care pathways for home health and hospice patients, aiming to reduce hospitalizations, improve symptom management, and strengthen patient and caregiver education.

Key Figures

Adults with cardiovascular disease: 127.9 million Prevalence of cardiovascular disease: 48.6% Cardiovascular disease costs: $422.3 billion

3 metrics

Adults with cardiovascular disease 127.9 million U.S. adults with some cardiovascular disease (2017–2020)

Prevalence of cardiovascular disease 48.6% Share of U.S. adults with some cardiovascular disease (2017–2020)

Cardiovascular disease costs $422.3 billion Direct and indirect costs to U.S. healthcare system

Market Reality Check

Price: $7.86 Vol: Volume 476,961 is 0.43x t...

low vol

$7.86 Last Close

Volume Volume 476,961 is 0.43x the 20-day average of 1,110,793, indicating subdued pre-news activity. low

Technical Shares at $7.86 trade 23.84% below the 52-week high of $10.32, but remain above the $7.24 200-day MA, signaling recovery from prior lows.

Peers on Argus

AVAH slipped 0.13% pre-announcement while peers were mixed: NHC (-0.88%), ARDT (...

AVAH slipped 0.13% pre-announcement while peers were mixed: NHC (-0.88%), ARDT (-0.44%), BKD (+0.37%), PIII (-19.03%), SEM (+1.08%). No coordinated sector move or shared news theme is evident.

Historical Context

5 past events · Latest: Jan 14 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 14	Guidance update	Positive	+10.0%	Updated full-year 2025 outlook and introduced initial full-year 2026 guidance.
Dec 17	Conference participation	Neutral	+1.6%	Announced presentation and investor meetings at J.P. Morgan Healthcare Conference.
Dec 04	Conference participation	Neutral	+2.1%	Planned virtual participation and webcast at BofA Securities Home Care Conference.
Nov 06	Earnings and outlook	Positive	-6.3%	Strong Q3 results with revenue growth, positive net income, and raised 2025 guidance.
Oct 21	Secondary offering	Neutral	-0.4%	Secondary sale of shares by existing holders; company received no proceeds.

Pattern Detected

Recent news has generally seen price moves align with event tone, except for a notable sell-off on strong Q3 2025 results and raised guidance.

Recent Company History

Over the last few months, Aveanna reported stronger Q3 2025 results with revenue of $621.9M, positive net income, and raised full-year 2025 guidance, yet the stock fell on that news. Subsequent items—conference participation and updated 2025/2026 guidance—saw modest positive reactions. A secondary offering by existing holders had minimal impact. Today’s CHAP certification fits into a narrative of operational and quality-focused progress alongside improving financial performance and capital markets activity.

Market Pulse Summary

This announcement highlights Aveanna’s CHAP certification for its Heartways heart failure program, e...

Analysis

This announcement highlights Aveanna’s CHAP certification for its Heartways heart failure program, emphasizing evidence-based protocols and structured disease management. It targets a substantial cardiovascular population, with 127.9 million U.S. adults affected and costs of $422.3 billion. Recent history includes stronger Q3 2025 financials, raised guidance, and an updated ownership report. Investors may watch how this certification translates into measurable quality metrics, hospitalization trends, and future financial disclosures.

Key Terms

heart failure, cardiovascular disease

2 terms

heart failure medical

"awarded a Disease Program Certification for Heart Failure under the CHAP"

A condition in which the heart cannot pump enough blood to meet the body's needs, causing fatigue, shortness of breath, fluid buildup, and reduced activity. It matters to investors because it drives demand for medicines, medical devices, hospital care, and long-term support services; outcomes, trial results, approvals, or changes in treatment guidelines can materially affect company revenues, healthcare costs, and market valuations. Think of it as a central pump losing efficiency and changing the economics of care.

cardiovascular disease medical

"127.9 million U.S. adults (48.6%) had some form of cardiovascular disease,"

A group of conditions that affect the heart and blood vessels, such as heart attacks, strokes and clogged arteries. Think of the cardiovascular system as a body’s plumbing and engine: when pipes narrow or the pump fails, treatment, devices and long-term care become necessary. Investors watch these diseases because their prevalence drives demand for drugs, devices and services, influences healthcare costs and insurer payouts, and affects workforce productivity and regulatory risk.

AI-generated analysis. Not financial advice.

ATLANTA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Community Health Accreditation Partner (CHAP), an independent, non-profit accrediting body for home and community-based healthcare, and Aveanna Healthcare (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care in the home, announced today that Aveanna Home Health and Hospice, a division of Aveanna Healthcare, has been awarded a Disease Program Certification for Heart Failure under the CHAP Disease Program Standards.

CHAP certification demonstrates that Aveanna Home Health and Hospice meets the industry’s highest nationally recognized standards. CHAP’s rigorous program evaluation focuses on program structure and function, quality metrics, advanced education for clinicians, and demonstrated self-management tools for patients.

“By achieving CHAP Disease Program Certification, Aveanna Home Health and Hospice has shown a commitment to excellence,” said Nathan DeGodt, CHAP President & CEO. “Their efforts to strengthen their clinical performance using evidence-based protocols means consistency becomes a result, not a goal.

“Achieving CHAP’s Enterprise Disease Program Certification for Heart Failure is a significant accomplishment, especially for an organization serving patients and families at Aveanna’s scale. This recognition reflects Aveanna’s commitment to evidence-based care, strong clinical education, and consistent disease management practices that help reduce hospitalizations and strengthen patient self-management,” added DeGodt. “Their Heartways program demonstrates how a thoughtful, well-structured framework can improve outcomes across diverse communities. We’re proud to partner with Aveanna as they continue advancing high-quality care for individuals living with heart failure.”

Aveanna’s Heartways is a scientifically validated care program that leads to improved outcomes for home health patients with heart disease. For Home Health patients, Heartways leads to improved outcomes by providing comprehensive patient education, guidance on daily routines, and monitoring symptoms to catch early warning signs, among other aspects. For hospice patients, the program offers palliative-focused protocols, including improved symptom management with tools that help caregivers recognize changes and provide compassionate support for the patient’s family.

Heart disease remains one of the leading chronic diseases in this country and one of the costliest to the nation’s healthcare system. According to the American Heart Association, between 2017 and 2020, 127.9 million U.S. adults (48.6%) had some form of cardiovascular disease, leading to direct and indirect costs of $422.3 billion.

“The Heartways program represents our commitment to quality, value, and innovation. This program delivers better outcomes for home health patients and greater comfort for our hospice patients,” said Shane Brinkerhoff, President of Home Health and Hospice at Aveanna Healthcare. “This program will improve the lives of home health patients with heart disease while reducing avoidable readmissions for our hospital partners. In addition, patients with end-stage heart disease will be able to experience a higher quality of life through our hospice care. We are proud to introduce this program to our patients and partners, and we are excited to work with CHAP as we help to redefine the national standards of quality care.”

About Aveanna Healthcare
Headquartered in Atlanta, Georgia, Aveanna Healthcare is one of the nation’s leading providers of home care, with locations in 38 states providing a broad range of pediatric and adult healthcare. Aveanna’s Home Health and Hospice Division provides a variety of services to patients and their families across 15 states. Aveanna’s services are designed to provide a high-quality, lower-cost alternative to prolonged hospitalization. For more information about Aveanna Healthcare, please contact communications@aveanna.com or visit https://www.aveanna.com. To learn more about the Heartways program, visit https://www.aveanna.com/heartways.

About Community Health Accreditation Partner, Inc. (CHAP)
CHAP is an independent, not-for-profit accrediting body for community-based healthcare organizations. Created in 1965, CHAP was the first to recognize the need and value for accreditation in community-based care. CHAP is the oldest national, community-based accrediting body, with more than 9,000 agencies currently accredited nationwide. Through “deeming authority” granted by the Centers for Medicare and Medicaid Services (CMS), CHAP has the regulatory authority to survey agencies providing home health, hospice, and home medical equipment services to determine if they meet the Medicare Conditions of Participation and CMS Quality Standards. CHAP’s purpose is to define and advance the highest standards of community-based care.

For more information about the CHAP Disease Program Certification, please visit the CHAP Learning Solutions website at https://chapinc.org/services/disease-program-certification/.

Media Contact

Aveanna Healthcare

communications@aveanna.com

CHAP

619-800-7255

education@chapinc.org

FAQ

What does CHAP Disease Program Certification for Heart Failure mean for Aveanna (AVAH)?

It means Aveanna's Heartways met CHAP standards for program structure and quality measures. According to Aveanna, the certification reflects adherence to evidence-based protocols, clinician education, and patient self-management tools designed to improve outcomes and reduce avoidable hospitalizations.

When did Aveanna (AVAH) announce the Heartways CHAP certification?

Aveanna announced the CHAP Disease Program Certification for Heart Failure on February 11, 2026. According to Aveanna, the recognition followed CHAP's program evaluation of clinical education, quality metrics, and patient-focused self-management tools.

How does the Heartways program improve care for home health patients under AVAH?

Heartways improves care by delivering comprehensive education, daily routine guidance, and symptom monitoring to catch early warning signs. According to Aveanna, these elements are part of an evidence-based framework aimed at improving outcomes and reducing readmissions for home health patients with heart disease.

What benefits does Heartways provide for hospice patients at Aveanna (AVAH)?

For hospice patients, Heartways offers palliative-focused protocols and improved symptom management tools for caregivers. According to Aveanna, the program helps caregivers recognize changes, deliver compassionate support, and enhance quality of life for patients with end-stage heart disease.

Does CHAP certification say anything about Heartways' clinical education and quality metrics?

Yes. CHAP's evaluation emphasizes clinician advanced education and measurable quality metrics within the program. According to Aveanna, certification confirms Heartways meets rigorous standards for clinical education, consistent disease-management practices, and demonstrated quality outcomes.